82 related articles for article (PubMed ID: 15954440)
1. [CTLA4-Ig].
Miyasaka N
Nihon Rinsho; 2005 May; 63 Suppl 5():751-5. PubMed ID: 15954440
[No Abstract] [Full Text] [Related]
2. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
3. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
4. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
5. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
Mukherjee S; Maiti PK; Nandi D
J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
[TBL] [Abstract][Full Text] [Related]
6. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
7. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis.
Israël-Assayag E; Fournier M; Cormier Y
J Immunol; 1999 Dec; 163(12):6794-9. PubMed ID: 10586079
[TBL] [Abstract][Full Text] [Related]
8. Interactions of CD80 and CD86 with CD28 and CTLA4.
Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
[TBL] [Abstract][Full Text] [Related]
9. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation.
Xu Z; Juan V; Ivanov A; Ma Z; Polakoff D; Powers DB; Dubridge RB; Wilson K; Akamatsu Y
J Immunol; 2012 Nov; 189(9):4470-7. PubMed ID: 23018459
[TBL] [Abstract][Full Text] [Related]
10. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.
Horspool JH; Perrin PJ; Woodcock JB; Cox JH; King CL; June CH; Harlan DM; St Louis DC; Lee KP
J Immunol; 1998 Mar; 160(6):2706-14. PubMed ID: 9510170
[TBL] [Abstract][Full Text] [Related]
11. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
12. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B.
Lane P; Haller C; McConnell F
Eur J Immunol; 1996 Apr; 26(4):858-62. PubMed ID: 8625979
[TBL] [Abstract][Full Text] [Related]
13. T cell proliferation-augmenting activities of the gene 3 protein derived from a phage library clone with CD80-binding activity.
Fukumoto T; Torigoe N; Ito Y; Kajiwara Y; Sugimura K
J Immunol; 1998 Dec; 161(12):6622-8. PubMed ID: 9862690
[TBL] [Abstract][Full Text] [Related]
14. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK
J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945
[TBL] [Abstract][Full Text] [Related]
15. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
[TBL] [Abstract][Full Text] [Related]
16. T-cell regulation by CD28 and CTLA-4.
Alegre ML; Frauwirth KA; Thompson CB
Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
[TBL] [Abstract][Full Text] [Related]
17. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis.
Shimoyama Y; Nagafuchi H; Suzuki N; Ochi T; Sakane T
J Rheumatol; 1999 Oct; 26(10):2094-101. PubMed ID: 10529123
[TBL] [Abstract][Full Text] [Related]
18. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells.
Park W; Weyand CM; Schmidt D; Goronzy JJ
Eur J Immunol; 1997 May; 27(5):1082-90. PubMed ID: 9174596
[TBL] [Abstract][Full Text] [Related]
20. Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics.
Larché M; Till SJ; Haselden BM; North J; Barkans J; Corrigan CJ; Kay AB; Robinson DS
J Immunol; 1998 Dec; 161(11):6375-82. PubMed ID: 9834128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
